- Home
- KLG vs CLDX Comparison
KLG vs CLDX Comparison
Compare KLG & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLG
- CLDX
- Stock Information
- Founded
- KLG 2022
- CLDX 1983
- Country
- KLG United States
- CLDX United States
- Employees
- KLG N/A
- CLDX N/A
- Industry
- KLG Packaged Foods
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KLG Consumer Staples
- CLDX Health Care
- Exchange
- KLG Nasdaq
- CLDX Nasdaq
- Market Cap
- KLG 1.6B
- CLDX 1.6B
- IPO Year
- KLG N/A
- CLDX 2008
- Fundamental
- Price
- KLG $15.94
- CLDX $23.78
- Analyst Decision
- KLG Sell
- CLDX Buy
- Analyst Count
- KLG 7
- CLDX 7
- Target Price
- KLG $18.14
- CLDX $64.83
- AVG Volume (30 Days)
- KLG 972.7K
- CLDX 1.1M
- Earning Date
- KLG 02-11-2025
- CLDX 02-24-2025
- Dividend Yield
- KLG 4.02%
- CLDX N/A
- EPS Growth
- KLG N/A
- CLDX N/A
- EPS
- KLG 0.78
- CLDX N/A
- Revenue
- KLG $2,719,000,000.00
- CLDX $9,976,000.00
- Revenue This Year
- KLG N/A
- CLDX N/A
- Revenue Next Year
- KLG N/A
- CLDX N/A
- P/E Ratio
- KLG $20.35
- CLDX N/A
- Revenue Growth
- KLG N/A
- CLDX 128.55
- 52 Week Low
- KLG $12.32
- CLDX $22.17
- 52 Week High
- KLG $24.63
- CLDX $53.18
- Technical
- Relative Strength Index (RSI)
- KLG 33.08
- CLDX 41.99
- Support Level
- KLG $15.49
- CLDX $22.17
- Resistance Level
- KLG $16.17
- CLDX $29.05
- Average True Range (ATR)
- KLG 0.62
- CLDX 1.57
- MACD
- KLG -0.16
- CLDX -0.26
- Stochastic Oscillator
- KLG 22.78
- CLDX 23.40
About KLG WK Kellogg Co
WK Kellogg is the second-largest cereal manufacturer in North America. Its cereal brands include Special K, Frosted Flakes, Raisin Bran, Froot Loops, Frosted Mini-Wheats, Kashi, Corn Flakes, Rice Krispies, Apple Jacks, and Bear Naked. The company was spun off from the former Kellogg business, now known as Kellanova, where the former firm's global snacks portfolio and international cereal brands are now housed. WK Kellogg, which began trading independently in October 2023, generates the bulk of its sales (about 88% of its fiscal 2023 base) from the US.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.